Clinical Trial Update: A Notch Signalling Pathway Inhibitor for Patients With Advanced Breast Cancer (0752-014) [Phase 1]

View source ↗

Summary

Phase 1 trial of a Notch signaling pathway inhibitor in patients with advanced breast cancer has completed; the study was sponsored by Merck Sharp & Dohme LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Notch signaling pathway inhibitor

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Advanced Breast Cancer, Other Solid Tumors | Phase 1 | Status: COMPLETED